| 000 | 01627 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515112506.0 | ||
| 264 | 0 | _c20081205 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a1464-2662 | ||
| 024 | 7 |
_a10.1111/j.1468-1293.2008.00558.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSprinz, E | |
| 245 | 0 | 0 |
_aLopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. _h[electronic resource] |
| 260 |
_bHIV medicine _cMay 2008 |
||
| 300 |
_a270-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xmethods |
| 650 | 0 | 4 | _aBrazil |
| 650 | 0 | 4 |
_aCD4 Lymphocyte Count _xmethods |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aPolymorphism, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aPyrimidinones _xadministration & dosage |
| 650 | 0 | 4 | _aRNA, Viral |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 |
_aViremia _xdrug therapy |
| 700 | 1 | _aBay, M B | |
| 700 | 1 | _aLazzaretti, R K | |
| 700 | 1 | _aJeffman, M W | |
| 700 | 1 | _aMattevi, V S | |
| 773 | 0 |
_tHIV medicine _gvol. 9 _gno. 5 _gp. 270-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1468-1293.2008.00558.x _zAvailable from publisher's website |
| 999 |
_c17833652 _d17833652 |
||